Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-05
2006-12-05
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S146000, C548S204000
Reexamination Certificate
active
07144904
ABSTRACT:
Composition, article of manufacture for and method of treating malaria in a human having an infestation ofPlasmodiumprotozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population ofPlasmodium.The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labeling for treating malaria. The substituents are detailed in the specification.
REFERENCES:
patent: 3274207 (1966-09-01), Kollonitsch et al.
patent: 3809754 (1974-05-01), Bertrand
patent: 3882110 (1975-05-01), Clemence et al.
patent: 4367233 (1983-01-01), Clark et al.
patent: 4406905 (1983-09-01), Zähner et al.
patent: 4457935 (1984-07-01), Iwao et al.
patent: 4457936 (1984-07-01), Draeger et al.
patent: 4558059 (1985-12-01), Kawasaki et al.
patent: 4736060 (1988-04-01), Tomuro et al.
patent: 4775675 (1988-10-01), Györgydeák et al.
patent: 4902700 (1990-02-01), Hayasi et al.
patent: 4914208 (1990-04-01), Jakob et al.
patent: 5084083 (1992-01-01), Lewis et al.
patent: 5106992 (1992-04-01), Magnin et al.
patent: 5169858 (1992-12-01), Rubin
patent: 5182402 (1993-01-01), Lewis et al.
patent: 5192781 (1993-03-01), Bru-Magniez et al.
patent: 5385922 (1995-01-01), Bron et al.
patent: 5393777 (1995-02-01), Crosa
patent: 5442073 (1995-08-01), Eicken et al.
patent: 5614520 (1997-03-01), Kondo et al.
patent: 5840739 (1998-11-01), Bergeron, Jr.
patent: 6080764 (2000-06-01), Chihiro et al.
patent: 6083966 (2000-07-01), Bergeron, Jr.
patent: 6147070 (2000-11-01), Facchini
patent: 6159983 (2000-12-01), Bergeron, Jr.
patent: 6372912 (2002-04-01), Döring et al.
patent: 6437143 (2002-08-01), Moinet et al.
patent: 6521652 (2003-02-01), Bergeron
patent: 6525080 (2003-02-01), Bergeron
patent: 6559315 (2003-05-01), Bergeron
patent: 6864270 (2005-03-01), Bergeron, Jr.
patent: 2002/0049316 (2002-04-01), Halbert et al.
patent: 2245 560 (1974-03-01), None
patent: 30 02 989 (1981-07-01), None
patent: 0 214 101 (1986-08-01), None
patent: 0 214 933 (1986-08-01), None
patent: 0 513 379 (1996-11-01), None
patent: 2 247 243 (1975-05-01), None
patent: 1292 170 (1972-10-01), None
patent: 1382887 (1975-05-01), None
patent: WO 94/11367 (1994-05-01), None
patent: WO 97/36885 (1997-10-01), None
patent: WO 97/42179 (1997-11-01), None
patent: WO 99/53039 (1999-10-01), None
patent: WO 00/16763 (2000-03-01), None
patent: WO 01/27119 (2001-04-01), None
Sasaki, T. et al.: Discovery of methyl-2-(2′-hydroxyphenyl)-2-oxazoline-4-carboxylate as a secondary metabolite fromActinomadurasp. The Journal of antibiotics, vol. 50, pp. 881-883, 1997.
Ryoo, I-J. et al.: A new cytotoxic phenylthiazoline, 4-methylaeruginoic acid, fromStreptomycessp. KCTC 9303. The Journal of Antibiotics, vol. 50, pp. 256-258, 1997.
Bergeron, R. J., et al., “The Desferrithiocin Pharmacophore,”J. Med. Chem., 37(10): 1411-1417 (1994).
Stahel, Erich, et al., “Iron Chelators: In Vitro Inhibitory Effect on the Liver Stage of Rodent and Human Malaria,”Am. J. Trop. Med. Hyg., 39(3):236-240 (1988).
Fritsch, Gerhard, et al., “Plasmodium falciparum: Inhibitionin Vitrowith Lactoferrin, Desferriferrithiocin, and Desferricrocin,”Experimental Parasitology, 63:1-9 (1987).
Henry, David W., “Chemotherapeutic Nitroheterocycles. Derivatives of 5-Nitrothiazole-2-carboxaldehyde and 5-Nitrothiazole-2-carboxylic Acid,”J. Med. Chem., 12(2):303-306 (1969).
Abstract for Accession No. 80:146142 from Chemical Abstract Database.
Abstract for Accession No. 83:206330 from Chemical Abstract Database.
Bergeron, R.J., “Iron: A Controlling Nutrient in Proliferative Processes,”Trends in Biochem. Sci., 11:133-136 (1986).
Bergeron, R.J., et al., “Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators,”J. Med. Chem., 34: 3182-3187 (1991).
Bergeron, et al., “A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One 1,2-Diethyl-3-Hydroxypyrid-4-One, and Deferoxamine,”Blood, 79(7): 1882-1890 (1992).
Bickel, et al., “Metabolic Properties of Actinomycetes. Ferrioxamine B,”Helv. Chim. Acta, 43:2129-2138 (1960).
Brittenham, G.M., “Pyridoxal Isonicotinoyl Hydrazone: An Effective Iron-Chelator After Oral Administration,”Semin. Hematol., 27(2): 112-116 (1990).
Finch, C.A., et al., “Ferrokinetics in Man,”Medicine(Baltimore), 49(1): 17-53 (1970).
Finch, C.A., et al., “Perspectives in Iron Metabolism,”N. Engl. J. Med., 306(25): 1520-1528 (1982).
Finch, C.A., and Huebers, H.A., “Iron Metabolism,”Clin. Physiol.Biochem., 4: 5-10 (1986).
Ganguly, P.K., and Gupta, B.M., “Antiviral Activity of Isoquinolines Carbazoles and Other Miscellaneous Synthetic Chemicals in Mice,”Indian J. Med. Res., 63(10): 1418-1425 (1975).
Grady, R.W., et al., “Rhodotorulic Acid-Investigation of its Potential as an Iron-Chelating Drug,”J. Pharmacol. Exp. Ther., 209(3): 342-348 (1979).
Grady, R.W., and Hershko, C., “HBED: A Potential Oral Iron Chelator,”Annals of the N.Y. Acad. Sci., 612: 361-368 (1990).
Guterman, S.K., et al., “Feasibility of Enterochelin as an Iron-Chelating Drug: Studies with Human Serum and a Mouse Model System,”Gen. Pharmac., 9: 123-127 (1978).
Hallberg, L., “Bioavailability of Dietary Iron in Man,”Ann. Rev. Nutri., 1:123-147 (1981).
Hoffbrand, A. V., “Transfusion Siderosis and Chelation Therapy,” inIron in Biochemistry and Medicine, II, pp. 499-527 (London & New York, 1980).
Kishore, V., et al., “Synthesis of α-Poly-[Nε-(2-aryl-Δ2-thiazoline-4-carbonyl)-L-lysines] with Antiviral Activity,”Indian J. Chem., 15B: 255-257 (1977).
Kontoghiorghes, G.J., et al., “1,2-Dimethyl-3-hydroxypyrid-4-one, an Orally Active Chelator for Treatment of Iron Overload,”Lancet, 1: 1294-1295 (1987).
O'Connell, M.J., et al., “The Role of Iron in Ferritin-and Haemosiderin-Mediated Lipid Peroxidation in Liposomes,”Biochem. J., 229(1): 135-139 (1985).
Po{hacek over (n)}ka, P., et al., “Mobilization of Iron from Reticulocytes: Identification of Pyridoxal Isonicotinoyl Hydrazone as a New Iron Chelating Agent,”FEBS Lett., 97(2): 317-321 (1979).
Raymond, K.N., and Carrano, C.J., “Coordination Chemistry and Microbial Iron Transport,”Acc. Chem. Res., 12: 183-190 (1979).
Seligman, P.A., et al., “Molecular Mechanisms of Iron Metabolism,” inThe Molecular Basis of Blood Diseases, pp. 219-244 (W.B. Saunders Company, 1987).
Thomas, C.E., et al., “Ferritin and Superoxide-Dependent Lipid Peroxidation,”J. Biol. Chem., 260:3275-3280 (1985).
Uhlir, L.C., et al., “Specific Sequestering Agents for the Actinides. 21. Synthesis and Initial Biological Testing of Octadentate Mixed Catecholate-hydroxypyridinonate Ligands,”J. Med. Chem., 36: 504-509 (1993).
Weintraub, L.R., et al., “The Treatment of Hemochromatosis by Phlebotomy,”Med. Clin. of N. America, 50(6): 1579-1590 (1966).
Bergeron, R.J., et al. “Evaluation of Desferrithiocin and its Synthetic Analogues as Orally Effective Iron Chelators”,J. of Med. Chem., 34(7): 2072-2078 (1991).
Bergeron, R.J., et al. “Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues,”J. Med. Chem., 42(13): 2432-2440 (1999).
Jalal, M.A.F., et al. “Structure of Anguibactin, a Unique Plasmid-Related Bacterial Siderophore from the Fish PathogenVibrio Anguillarum,” J. Am. Chem. Soc., 111(1): 292-296 (1989).
Ullmanns Encyclopedia of Industrial Chemistry, 5thEdition, vol. A 14, “Ion Exchangers,” pp. 446-456.
Bergeron, R.J., et al., “A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues With Desferrioxamine B in aCebusMonkey Model,
Aulakh Charanjit S.
Hamilton Brook Smith & Reynolds P.C.
University of Florida Research Foundation Inc.
LandOfFree
Iron binding agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Iron binding agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iron binding agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3717615